PP2A/B55α substrate recruitment as defined by the retinoblastoma-related protein p107

  1. Holly Fowle
  2. Ziran Zhao
  3. Qifang Xu
  4. Jason S Wasserman
  5. Xinru Wang
  6. Mary Adeyemi
  7. Felicity Feiser
  8. Alison N Kurimchak
  9. Diba Atar
  10. Brennan C McEwan
  11. Arminja N Kettenbach
  12. Rebecca Page
  13. Wolfgang Peti
  14. Roland L Dunbrack Jr.
  15. Xavier Graña  Is a corresponding author
  1. Temple University Lewis Katz School of Medicine, United States
  2. Fox Chase Cancer Center, United States
  3. University of Arizona, United States
  4. Hitchcock Medical Center at Dartmouth, United States
  5. UConn Health, United States

Abstract

Protein phosphorylation is a reversible post-translation modification essential in cell signaling. This study addresses a long-standing question as to how the most abundant serine/threonine Protein Phosphatase 2 (PP2A) holoenzyme, PP2A/B55α, specifically recognizes substrates and presents them to the enzyme active site. Here, we show how the PP2A regulatory subunit B55α recruits p107, a pRB-related tumor suppressor and B55α substrate. Using molecular and cellular approaches, we identified a conserved region 1 (R1, residues 615-626) encompassing the strongest p107 binding site. This enabled us to identify an 'HxRVxxV619-625' short linear motif (SLiM) in p107 as necessary for B55α binding and dephosphorylation of the proximal pSer-615 in vitro and in cells. Numerous B55α/PP2A substrates, including TAU, contain a related SLiM C-terminal from a proximal phosphosite, 'p[ST]-P-x(4,10)-[RK]-V-x-x-[VI]-R'. Mutation of conserved SLiM residues in TAU dramatically inhibits dephosphorylation by PP2A/B55α, validating its generality. A data-guided computational model details the interaction of residues from the conserved p107 SLiM, the B55α groove, and phosphosite presentation. Altogether these data provide key insights into PP2A/B55α mechanisms of substrate recruitment and active site engagement, and also facilitate identification and validation of new substrates, a key step towards understanding PP2A/B55α role in multiple cellular processes.

Data availability

Raw MS data for the the data depicted in Figure 6B are available at MassIVEhttps://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=9c21e08f6a524d7097e8bd45f0d2f375PXD028612.All NMR chemical shifts (Figure 1E-F) have been deposited in the BioMagResBank (BMRB: 28091).Source code folder (PeptideDock_sourceCode) for Figure 7 is a C# project, including retrieval of peptide structures from PDB and other sources such as PISCES, and calculation of distances and data analyses. https://github.com/DunbrackLab/PP2A_PeptideDock.All other data generated or analysed during this study are included in the manuscript and supporting files. Source Data files have been provided.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Holly Fowle

    Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Ziran Zhao

    Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Qifang Xu

    Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Jason S Wasserman

    Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Xinru Wang

    Department of Chemistry and Biochemistry, University of Arizona, Tucson, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5994-707X
  6. Mary Adeyemi

    Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Felicity Feiser

    Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Alison N Kurimchak

    Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Diba Atar

    Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Brennan C McEwan

    Department of Biochemistry and Cell Biology, Hitchcock Medical Center at Dartmouth, Lebanon, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Arminja N Kettenbach

    Department of Biochemistry and Cell Biology, Hitchcock Medical Center at Dartmouth, Lebanon, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3979-4576
  12. Rebecca Page

    Department Cell Biology,, UConn Health, Farmington, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Wolfgang Peti

    6Department Molecular Biology and Biophysics, UConn Health, Farmington, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Roland L Dunbrack Jr.

    Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Xavier Graña

    Fels Institute for Cancer Research and Molecular Biology, Temple University Lewis Katz School of Medicine, Philadelphia, United States
    For correspondence
    xgrana@temple.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7134-0473

Funding

National Institute of General Medical Sciences (R01 GM117437)

  • Xavier Graña

National Cancer Institute (R03 CA216134-01)

  • Xavier Graña

WW Smith charitable Trust Award (no reference number)

  • Xavier Graña

National Cancer Institute (P30 CA006927)

  • Roland L Dunbrack Jr.
  • Xavier Graña

National Cancer Institute (U54 CA221704)

  • Holly Fowle
  • Ziran Zhao

National Institute of General Medical Sciences (R01GM134683)

  • Wolfgang Peti

National Institute of Neurological Disorders and Stroke (R01NS091336)

  • Wolfgang Peti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. William C Hahn, Dana-Farber Cancer Institute, United States

Version history

  1. Received: September 17, 2020
  2. Preprint posted: March 3, 2021 (view preprint)
  3. Accepted: October 17, 2021
  4. Accepted Manuscript published: October 18, 2021 (version 1)
  5. Version of Record published: November 8, 2021 (version 2)
  6. Version of Record updated: June 28, 2022 (version 3)

Copyright

© 2021, Fowle et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,016
    views
  • 283
    downloads
  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Holly Fowle
  2. Ziran Zhao
  3. Qifang Xu
  4. Jason S Wasserman
  5. Xinru Wang
  6. Mary Adeyemi
  7. Felicity Feiser
  8. Alison N Kurimchak
  9. Diba Atar
  10. Brennan C McEwan
  11. Arminja N Kettenbach
  12. Rebecca Page
  13. Wolfgang Peti
  14. Roland L Dunbrack Jr.
  15. Xavier Graña
(2021)
PP2A/B55α substrate recruitment as defined by the retinoblastoma-related protein p107
eLife 10:e63181.
https://doi.org/10.7554/eLife.63181

Share this article

https://doi.org/10.7554/eLife.63181

Further reading

    1. Biochemistry and Chemical Biology
    2. Neuroscience
    Maximilian Nagel, Marco Niestroj ... Marc Spehr
    Research Article

    In most mammals, conspecific chemosensory communication relies on semiochemical release within complex bodily secretions and subsequent stimulus detection by the vomeronasal organ (VNO). Urine, a rich source of ethologically relevant chemosignals, conveys detailed information about sex, social hierarchy, health, and reproductive state, which becomes accessible to a conspecific via vomeronasal sampling. So far, however, numerous aspects of social chemosignaling along the vomeronasal pathway remain unclear. Moreover, since virtually all research on vomeronasal physiology is based on secretions derived from inbred laboratory mice, it remains uncertain whether such stimuli provide a true representation of potentially more relevant cues found in the wild. Here, we combine a robust low-noise VNO activity assay with comparative molecular profiling of sex- and strain-specific mouse urine samples from two inbred laboratory strains as well as from wild mice. With comprehensive molecular portraits of these secretions, VNO activity analysis now enables us to (i) assess whether and, if so, how much sex/strain-selective ‘raw’ chemical information in urine is accessible via vomeronasal sampling; (ii) identify which chemicals exhibit sufficient discriminatory power to signal an animal’s sex, strain, or both; (iii) determine the extent to which wild mouse secretions are unique; and (iv) analyze whether vomeronasal response profiles differ between strains. We report both sex- and, in particular, strain-selective VNO representations of chemical information. Within the urinary ‘secretome’, both volatile compounds and proteins exhibit sufficient discriminative power to provide sex- and strain-specific molecular fingerprints. While total protein amount is substantially enriched in male urine, females secrete a larger variety at overall comparatively low concentrations. Surprisingly, the molecular spectrum of wild mouse urine does not dramatically exceed that of inbred strains. Finally, vomeronasal response profiles differ between C57BL/6 and BALB/c animals, with particularly disparate representations of female semiochemicals.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Claudia D Consalvo, Adedeji M Aderounmu ... Brenda L Bass
    Research Article

    Invertebrates use the endoribonuclease Dicer to cleave viral dsRNA during antiviral defense, while vertebrates use RIG-I-like Receptors (RLRs), which bind viral dsRNA to trigger an interferon response. While some invertebrate Dicers act alone during antiviral defense, Caenorhabditis elegans Dicer acts in a complex with a dsRNA binding protein called RDE-4, and an RLR ortholog called DRH-1. We used biochemical and structural techniques to provide mechanistic insight into how these proteins function together. We found RDE-4 is important for ATP-independent and ATP-dependent cleavage reactions, while helicase domains of both DCR-1 and DRH-1 contribute to ATP-dependent cleavage. DRH-1 plays the dominant role in ATP hydrolysis, and like mammalian RLRs, has an N-terminal domain that functions in autoinhibition. A cryo-EM structure indicates DRH-1 interacts with DCR-1’s helicase domain, suggesting this interaction relieves autoinhibition. Our study unravels the mechanistic basis of the collaboration between two helicases from typically distinct innate immune defense pathways.